TY - JOUR
T1 - Beyond CD19 CAR-T cells in lymphoma
AU - Leung, Wingchi K.
AU - Ayanambakkam, Adanma
AU - Heslop, Helen E.
AU - Hill, La Quisa C.
N1 - Funding Information:
HEH has equity in AlloVir and Marker Therapeutics, has served on advisory boards for Tessa Therapeutics, Novartis, Gilead Biosciences, Kiadis, GSK and Fresh Wind Biotherapeutics and has research funding from Kuur Therapeutics and Tessa Therapeutics. WL, AA, and LCH have no conflicts to disclose.The authors thank Catherine Gillespie for editing the manuscript and Walter Mejia for formatting of manuscript figures. WKL is supported by the Cancer Research Trust New Zealand, a Murray Jackson Clinical Fellowship, and a HSANZ New Investigator Scholarship. HEH and LCH are supported by the National Cancer Institute (P50CA126752 and P30CA125123) SU2C/AACR 604817 Meg Vosburg T cell Lymphoma Dream Team, and the Lxeukemia and Lymphoma Society. Stand Up to Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. AA was supported by CPRIT grant RP160283.
Funding Information:
WKL is supported by the Cancer Research Trust New Zealand , a Murray Jackson Clinical Fellowship, and a HSANZ New Investigator Scholarship . HEH and LCH are supported by the National Cancer Institute ( P50CA126752 and P30CA125123 ) SU2C/AACR 604817 Meg Vosburg T cell Lymphoma Dream Team , and the Lxeukemia and Lymphoma Society . Stand Up to Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. AA was supported by CPRIT grant RP160283 .
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2022/2
Y1 - 2022/2
N2 - Adoptive transfer of CD19-specific chimeric antigen receptor T-cells (CAR-T cells) has transformed the treatment paradigm of relapsed/refractory (R/R) CD19 B-cell malignancies, dramatically improving remission rates and cures in patients with chemo-refractory disease. However, the applicability of CD19 CAR-T cells is limited to B cell malignancies and antigen loss can result in treatment failure, prompting the exploration of alternative targets to overcome tumor escape via CD19 antigen loss, as well as extend the CAR-T cell platform to treat Hodgkin and T cell lymphomas. This review highlights recent clinical trials testing CAR-T cell targets beyond CD19.
AB - Adoptive transfer of CD19-specific chimeric antigen receptor T-cells (CAR-T cells) has transformed the treatment paradigm of relapsed/refractory (R/R) CD19 B-cell malignancies, dramatically improving remission rates and cures in patients with chemo-refractory disease. However, the applicability of CD19 CAR-T cells is limited to B cell malignancies and antigen loss can result in treatment failure, prompting the exploration of alternative targets to overcome tumor escape via CD19 antigen loss, as well as extend the CAR-T cell platform to treat Hodgkin and T cell lymphomas. This review highlights recent clinical trials testing CAR-T cell targets beyond CD19.
KW - Antigens, CD19/immunology
KW - Humans
KW - Immunotherapy, Adoptive
KW - Lymphoma/immunology
KW - Neoplasm Recurrence, Local/immunology
KW - Receptors, Antigen, T-Cell/genetics
KW - Receptors, Chimeric Antigen/genetics
KW - T-Lymphocytes/immunology
UR - http://www.scopus.com/inward/record.url?scp=85119278079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119278079&partnerID=8YFLogxK
U2 - 10.1016/j.coi.2021.09.009
DO - 10.1016/j.coi.2021.09.009
M3 - Review article
C2 - 34800921
AN - SCOPUS:85119278079
SN - 0952-7915
VL - 74
SP - 46
EP - 52
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
ER -